Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 4/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.39 |
| ▸ | FADS1 | O60427 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443577 | 1.00 | SRD5A1 (0.47) | SRD5A1SRD5A2HTR2CHTR2AHTR2B | |
| SCHEMBL1859026 | 1.00 | SRD5A1 (0.47) | SRD5A1SRD5A2HTR2CHTR2AHTR2B | |
| SCHEMBL1857673 | 1.00 | SRD5A1 (0.47) | SRD5A1SRD5A2HTR2CHTR2AHTR2B | |
| SCHEMBL29443582 | 1.00 | SRD5A1 (0.47) | SRD5A1SRD5A2HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL26664227 | 0.98 | SRD5A1 (0.46) | SRD5A1SRD5A2HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL17579539 | 0.98 | SRD5A1 (0.46) | SRD5A1SRD5A2HTR2CHTR2AHTR2B | |
| SCHEMBL3535473 | 0.89 | KDM1A (0.45) | SRD5A1SRD5A2HTR2CHTR2AHTR2B | |
| SCHEMBL22652225 | 0.89 | KDM1A (0.45) | SRD5A1SRD5A2HTR2CHTR2AHTR2B | |
| SCHEMBL1004804 | 0.86 | HTR2C (0.47) | HTR2CHTR2AHTR2BKDM1ASLC6A4 | |
| SCHEMBL7895243 | 0.86 | HTR2C (0.47) | HTR2CHTR2AHTR2BKDM1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409917-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-09 | — | — | US | claimed |
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-01-22 | — | — | US | claimed |
| EP-3964518-B1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| CN-114206335-B | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12157755-B2 | CD73 inhibitor, preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-12-03 | — | — | US | disclosed |
| EP-4446314-A2 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-3962479-B1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4272836-A2 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-1989206-B1 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2402334-A1 | Inhibitors of E1 Activating Enzymes | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| CN-101379061-A | E1 activating enzyme inhibitor | MILLENNIUM PHARM INC (US) | 2009-03-04 | — | — | CN | disclosed |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | SRD5A1 744/4885SRD5A2 1449/4885HTR2C 4747/4885 |
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | SRD5A1 3372/4885SRD5A2 3659/4885HTR2C 2055/4885 |
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX3 | SRD5A1 3859/4885SRD5A2 3935/4885HTR2C 218/4885 |
| US-12157755-B2 | CD73 inhibitor, preparation method therefor and application thereof | ENTPD5, ENTPD1, NT5E | SRD5A1 2251/4885SRD5A2 3191/4885HTR2C 3247/4885 |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | SRD5A1 744/4885SRD5A2 1449/4885HTR2C 4747/4885 |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, ALDH18A1 | SRD5A1 41/4885SRD5A2 127/4885HTR2C 3891/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | SRD5A1 744/4885SRD5A2 1449/4885HTR2C 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.